Login to Your Account



Cystic fibrosis moves forward: New MOA and imaging tech

By Brian Orelli
Staff Writer

Monday, May 1, 2017

On Thursday, cystic fibrosis powerhouse Vertex Pharmaceuticals Inc. reported solid first-quarter sales of its drugs, Kalydeco (ivacaftor) and Orkambi (lumacaftor/ivacaftor), designed to modulate CFTR, which is mutated in cystic fibrosis patients, but it was the pipeline of next-generation drugs that received the most attention.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription